Vicor Technologies Interviewed by CEOCFO; Exciting Developments and Progress to Commercialize Patented Cardiac Risk Stratification Technology Discussed
SOURCE:
Vicor Technologies, Inc.
2008-04-07 06:10:00
Vicor Technologies Interviewed by CEOCFO; Exciting Developments and Progress to Commercialize Patented Cardiac Risk Stratification Technology Discussed
BOCA RATON, FL–( EMWNews – April 7, 2008) – Vicor Technologies, Inc. (
development-stage company commercializing the PD2i Cardiac Analyzer,
announced that President and CEO Mr. David H. Fater provided a
comprehensive, in-depth interview to CEOCFO.
In the interview, Mr. Fater discussed the Collaborative Research and
Development Agreement (CRADA) that has been signed with the U.S. Army to
use the PD2i technology to triage wounded soldiers. He stated that this
effort could lead to 2008 Food and Drug Administration approval for
military and civilian applications in the trauma and emergency response
arenas resulting in revenue generation.
The status of Vicor’s application seeking FDA 510(k) approval for its PD2i
Cardiac Analyzer, and progress of the VITAL Trial, to risk stratify
individuals for SCD, was reviewed in detail. Vicor believes its PD2i
accurately risk stratifies patients who are at high or low risk of
suffering SCD within a six-month time frame, and who may need a costly
Implantable Cardioverter Defibrillator (ICD) implantation.
Mr. Fater commented, “The issue of ICD implantation and risk stratification
is extremely important to the Company since we believe Vicor is in the
right place at the right time with the PD2i Cardiac Analyzer, especially
since in a Wall Street Journal article this week, a Duke University
cardiologist described the diagnostic situation for SCD as in ‘chaos’.”
To read this detailed, comprehensive CEOCFO interview, please access
directly by clicking on the link below:
http://ceocfointerviews.com/interviews/VCRT-Vicor.htm
About Sudden Cardiac Death (SCD)
SCD is the leading killer in the U.S. with over 500,000 annual deaths. It
is a fatal arrhythmic event and is different than a heart attack. A heart
attack is analogous to a plumbing problem, where the blood supply to a part
of the heart is choked off, leading to the death of that portion of the
heart muscle. SCD is theorized to be caused by a breakdown of the normal
neurological communication pattern between the heart and brain, more like
an electrical problem, which can lead to a rapid, life threatening heart
rhythm that is usually fatal within minutes, if untreated. It is swift,
unexpected, and often has no advance warning or symptoms.
About Vicor Technologies, Inc.
Vicor’s medical device, the PD2i Cardiac Analyzer, is based on a patented,
proprietary algorithm. Vicor believes the PD2i Cardiac Analyzer accurately
risk stratifies patients who are at high or low risk of suffering a fatal
arrhythmic event or SCD within a six-month time frame.
Vicor’s PD2i Cardiac Analyzer addresses a significant health care issue
involving a patient cohort of at least 12,000,000 patients. This patient
cohort is composed of the MADIT-II (Multicenter Automatic Defibrillator
Implantation Trial II)/SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial) patient population. Many in this patient cohort may need an
Implantable Cardioverter Defibrillator (ICD) as life saving therapy.
However, recent registry studies have noted that over 70% of implanted
ICD’s never have an appropriate firing. This over-implantation has led to a
substantial and unnecessary medical cost burden. There is also the risk of
not identifying patients who need this life-saving therapy because current
criteria do not provide physicians the ability to accurately risk stratify
their patients.
The PD2i Cardiac Analyzer contains the patented PD2i algorithm which
provides a method for evaluating electrophysiological potentials with a
high sensitivity and high specificity used to predict future pathological
events i.e. fatal cardiac arrhythmias. The PD2i algorithm detects
deterministic, low-dimensional excursions in nonstationary heartbeat
intervals. The PD2i algorithm uses an analytic measure that is
deterministic and nonlinear. It is based on caused variation in data; does
not require data stationarity and actually tracks nonstationary changes in
the data. It is sensitive to chaotic as well as nonchaotic linear data.
The appearance of name-brand institutions or products in this media release
does not constitute endorsement by the U.S. Army Medical Research and
Materiel Command, the Department of the Army, Department of Defense or the
U.S. Government of the information, products or services contained therein.
For more information visit the Vicor Technologies web site
About CEOCFO
A bi-weekly print online publication — marketing engine featuring:
publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ,
AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V) stock exchanges,
Investment & Money Management Ideas. To access the website please go to
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans
and expectations that are subject to uncertainties and risks, which could
cause our future results to differ materially. The following factors,
among others, could cause our actual results to differ: our ability to
continue to receive financing sufficient to complete the critical clinical
trials; our ability to continue as a going concern; our ability to
successfully develop products based on our technologies; our ability to
obtain and maintain adequate levels of third-party reimbursement for our
products; the impact of competitive products and pricing; our ability to
receive regulatory approval for our products; the ability of third-party
contract research organizations to perform preclinical testing and clinical
trials for our technologies; the ability of third-party manufacturers to
manufacture our products; our ability to retain the services of our key
personnel; our ability to market and sell our products successfully; our
ability to protect our intellectual property; product liability; changes in
federal income tax laws and regulations; general market conditions in the
medical device and pharmaceutical industries; and changes in laws and
regulations. Forward-looking statements in this press release speak only
as of the date of the press release, and we assume no obligation to update
forward-looking statements or the reasons why actual results could differ.
| INVESTOR CONTACT: Andrew Brown ROI Associates 212.495.0202 [email protected] Mike Dodge COMPANY CONTACT: |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
